Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
Compugen (NASDAQ:CGEN) announced its upcoming presentation at ESMO 2025 in Berlin, Germany. The presentation will feature a pooled analysis of data from three Phase 1 trials evaluating COM701 in platinum resistant ovarian cancer patients.
The analysis includes data from trials testing COM701 as both monotherapy and combination therapy in heavily pretreated patients. Dr. Oladapo Yeku from Massachusetts General Hospital will present the findings on October 18, 2025 at 12:00-12:45 CEST. The poster presentation (#1196P) will subsequently be available on Compugen's website.
Compugen (NASDAQ:CGEN) ha annunciato la sua prossima presentazione al ESMO 2025 che si terr脿 a Berlino, Germania. La presentazione includer脿 un analisi combinata dei dati provenienti da tre studi di Fase 1 che valutano COM701 in pazienti con carcinoma ovarico resistente al platino.
L'analisi comprende dati da studi che testano COM701 sia come monoterapia che in terapia combinata in pazienti con pretrattamenti intensivi. Il dott. Oladapo Yeku del Massachusetts General Hospital presenter脿 i risultati il 18 ottobre 2025 dalle 12:00 alle 12:45 CEST. La presentazione poster (#1196P) sar脿 poi disponibile sul sito web di Compugen.
Compugen (NASDAQ:CGEN) anunci贸 su pr贸xima presentaci贸n en el ESMO 2025 en Berl铆n, Alemania. La presentaci贸n incluir谩 un an谩lisis combinado de datos de tres ensayos de Fase 1 que eval煤an COM701 en pacientes con c谩ncer de ovario resistente al platino.
El an谩lisis incluye datos de ensayos que prueban COM701 tanto como monoterapia como en terapia combinada en pacientes con tratamientos previos extensos. El Dr. Oladapo Yeku del Massachusetts General Hospital presentar谩 los hallazgos el 18 de octubre de 2025 de 12:00 a 12:45 CEST. La presentaci贸n en p贸ster (#1196P) estar谩 disponible posteriormente en la p谩gina web de Compugen.
Compugen (NASDAQ:CGEN)鞚� 霃呾澕 氩犽ゼ毽办棎靹� 鞐措Μ電� ESMO 2025鞐愳劀 瓿� 氚滍憸頃� 鞓堨爼鞛勳潉 鞎岆牳鞀惦媹雼�. 鞚措矆 氚滍憸鞐愳劀電� 氚标笀 雮挫劚 雮滌唽鞎� 頇橃瀽毳� 雽�靸侅溂搿� 頃� 3瓯挫潣 1靸� 鞛勳儊鞁滍棙 雿办澊韯半ゼ 韱淀暕 攵勳劃頃� 瓴瓣臣臧� 靻岅皽霅╇媹雼�.
攵勳劃鞐愲姅 COM701鞚� 雼弲鞖旊矔 氚� 氤戩毄鞖旊矔鞙茧 韴棳頃� 雼ろ殞 旃橂 頇橃瀽鞚� 雿办澊韯瓣皜 韽暔霅橃柎 鞛堨姷雼堧嫟. 毵れ偓於旍劯旄� 膦呿暕氤戩洂鞚� 鞓澕雼ろ彫 鞓堨繝 氚曥偓臧� 2025雲� 10鞗� 18鞚� 12:00~12:45 CEST鞐� 鞐瓣惮 瓴瓣臣毳� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 韽姢韯� 氚滍憸(#1196P)電� 鞚错泟 Compugen 鞗轨偓鞚错姼鞐愳劀 頇曥澑頃� 靾� 鞛堨姷雼堧嫟.
Compugen (NASDAQ:CGEN) a annonc茅 sa prochaine pr茅sentation au ESMO 2025 脿 Berlin, en Allemagne. La pr茅sentation comprendra une analyse regroup茅e des donn茅es de trois essais de Phase 1 茅valuant COM701 chez des patientes atteintes d鈥檜n cancer de l鈥檕vaire r茅sistant au platine.
L鈥檃nalyse inclut des donn茅es d鈥檈ssais testant COM701 en monoth茅rapie et en th茅rapie combin茅e chez des patientes fortement pr茅trait茅es. Le Dr Oladapo Yeku du Massachusetts General Hospital pr茅sentera les r茅sultats le 18 octobre 2025 de 12h00 脿 12h45 CEST. La pr茅sentation sous forme de poster (#1196P) sera ensuite disponible sur le site web de Compugen.
Compugen (NASDAQ:CGEN) k眉ndigte seine bevorstehende Pr盲sentation auf dem ESMO 2025 in Berlin, Deutschland, an. Die Pr盲sentation umfasst eine zusammengefasste Analyse von Daten aus drei Phase-1-Studien, in denen COM701 bei Patienten mit Platin-resistentem Eierstockkrebs untersucht wurde.
Die Analyse beinhaltet Daten aus Studien, in denen COM701 sowohl als Monotherapie als auch in Kombinationstherapie bei stark vorbehandelten Patienten getestet wurde. Dr. Oladapo Yeku vom Massachusetts General Hospital wird die Ergebnisse am 18. Oktober 2025 von 12:00 bis 12:45 Uhr MESZ vorstellen. Die Posterpr盲sentation (#1196P) wird anschlie脽end auf der Website von Compugen verf眉gbar sein.
- None.
- None.
HOLON,
Poster details:聽
Title: COM701 in Ovarian Cancer: A Pooled Analysis of 3 Phase 1 Clinical Trials聽
Speaker:聽Dr. Oladapo Yeku, Massachusetts General Hospital,
Poster presentation number: 1196P
Date of poster presentation: Saturday, October 18; 12:00-12:45 CEST
The poster will be available in the publications section of Compugen's website,
础产辞耻迟听颁辞尘辫耻驳别苍听
Compugen聽is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen鈩�) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902,聽a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies.聽GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage聽immuno-oncology programs consists of research programs aiming to address various mechanisms to activate the immune system against cancer. Compugen聽is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Vice President, Head of Investor Relations and Corporate Communications
贰尘补颈濒:听[email protected]
Tel: +1聽(628)聽241-0071
View original content:
SOURCE Compugen Ltd.
FAQ
When and where will Compugen (CGEN) present its COM701 trial data at ESMO 2025?
What type of data will Compugen (CGEN) present at ESMO 2025?
Who will present Compugen's (CGEN) COM701 trial data at ESMO 2025?
Where can investors access Compugen's (CGEN) ESMO 2025 poster presentation?
